A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)

enthalten in: Annals of oncology | 2016

von Smyth, E. | Rowley, S. | Allum, W. | +17

MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell lines

enthalten in: Annals of oncology | 2016

von Lote, H. | Zito, D. | Burke, R. | +4

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)

enthalten in: Annals of oncology | 2013

von Obasaju, C. | Bowman, L. | Wang, P. | +7

Histology and outcomes of newly detected lung lesions in melanoma patients

enthalten in: Annals of oncology | 2012

von Smyth, E. | Hsu, M. | Panageas, K. | +1